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Because it is the product of glycolysis and main substrate for mitochondrial respiration,
lactate is the central metabolic intermediate in cerebral energy substrate delivery. Our
recent studies on healthy controls and patients following traumatic brain injury (TBI)
using [6,6-2H2]glucose and [3-13C]lactate, along with cerebral blood flow (CBF) and
arterial-venous (jugular bulb) difference measurements for oxygen, metabolite levels,
isotopic enrichments and 13CO2 show a massive and previously unrecognized mobilization
of lactate from corporeal (muscle, skin, and other) glycogen reserves in TBI patients who
were studied 5.7 ± 2.2 days after injury at which time brain oxygen consumption and
glucose uptake (CMRO2 and CMRgluc, respectively) were depressed. By tracking the
incorporation of the 13C from lactate tracer we found that gluconeogenesis (GNG) from
lactate accounted for 67.1 ± 6.9%, of whole-body glucose appearance rate (Ra) in TBI,
which was compared to 15.2 ± 2.8% (mean ± SD, respectively) in healthy, well-nourished
controls. Standard of care treatment of TBI patients in state-of-the-art facilities by talented
and dedicated heath care professionals reveals presence of a catabolic Body Energy State
(BES). Results are interpreted to mean that additional nutritive support is required to fuel
the body and brain following TBI. Use of a diagnostic to monitor BES to provide health care
professionals with actionable data in providing nutritive formulations to fuel the body and
brain and achieve exquisite glycemic control are discussed. In particular, the advantages
of using inorganic and organic lactate salts, esters and other compounds are examined. To
date, several investigations on brain-injured patients with intact hepatic and renal functions
show that compared to dextrose + insulin treatment, exogenous lactate infusion results
in normal glycemia.
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GLYCOLYSIS MAKES LACTATE CONTINUOUSLY
As described by editor Schurr in the introductory chapter, the
conclusion that glycolysis makes lactate is a central issue; by defi-
nition, glycolysis makes lactate (Schurr, 2014). Whether glycolysis
produces acid, or not, is a different, and perhaps unresolved
issue. That glycolysis produces lactate normally, under fully aer-
obic conditions is perhaps best exemplified by results of studies
on resting muscle (Stanley et al., 1986; Richardson et al., 1998;
Bergman et al., 1999b), the healthy beating heart (Gertz et al.,
1981, 1988; Bergman et al., 2009), the normally functioning
brain (van Hall et al., 2009; Wyss et al., 2011; Glenn et al.,
2015), and in other diverse tissues following enteral carbohydrate
nutrition (Foster, 1984; Meyer et al., 2002). That lactate produc-
tion is greatly increased during muscular exercise can be readily
observed (Stanley et al., 1985; Mazzeo et al., 1986; Bergman et al.,
1999b; Messonnier et al., 2013), but again lactate production
in working muscle during graded exercise up to maximum is
not due to oxygen insufficiency (Richardson et al., 1998), and
for that matter, the elevation in circulating lactate concentration
during prolonged exercise cannot be attributed solely to net
lactate release from working muscle (Ahlborg and Felig, 1982;
Brooks et al., 1998). Rather, some other large tissue bed, perhaps
the integument (Johnson and Fusaro, 1972) is responsible for ele-
vated blood lactate concentration and turnover rates when there
is no net lactate release from working muscle (Ahlborg and Felig,
1982; Brooks et al., 1998).
Importance of the fact that lactate can be produced in par-
ticular cellular compartments and from those sites can enter
the interstitium and vasculature from where it can reach adja-
cent or anatomically distributed cells, organs, and tissues to
affect important functions was recognized in 1984 (Brooks,
1984). At that time data from several sources were evaluated
in light of original data on glucose and lactate fluxes in rest-
ing and exercising, untrained and endurance trained labora-
tory rats (Brooks and Donovan, 1983; Donovan and Brooks,
1983). The exchange of lactate among cellular sites of produc-
tion and removal was termed the “Lactate Shuttle” (Brooks,
1984).
In humans and other mammals the extent of lactate pro-
duction is typically overlooked because removal (disposal) rate
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balances production (appearance) rate. In other words, with typ-
ical concentration measurement technology low and stable blood
lactate levels belie high turnover (production and removal) rates.
And, even when arterial-venous [a-v] concentration differences
and tissue blood flow measurements are available, in the absence
of isotope tracer technology turnover rate is unknown because
of rapid turnover within the tissue bed of interest. Restated,
basing conclusions about the dynamics of lactate or any other
metabolite solely on concentration data is intellectually equiv-
alent to taking the US census in the morning and evening of
the same day, and then upon seeing no significant change in
population numbers concluding that nothing happened in the
population during that day. Happily, many entered the popula-
tion, and regrettably also, some exited. Hence, concentration data
provide an incomplete view of lactate turnover (flux) except in
conditions of sudden and large changes when homeostatic imbal-
ances in the relationship between production and removal are
indicated.
In resting or working muscle (Stanley et al., 1986; Bergman
et al., 1999b), the heart in normal sinus rhythm at rest or under
load (Gertz et al., 1981, 1988; Bergman et al., 2009), and in other
tissues such as skin (Johnson and Fusaro, 1972), lactate produc-
tion and net release are the norm. Restated, idling or working
skeletal muscles and heart simultaneously produce and consume
lactate (Stanley et al., 1986; Bergman et al., 1999b) as shown by
means of simultaneous tissue blood flow arterial-venous differ-
ence ([a-v], [a-v], or AVD) measures for lactate concentration
and isotopic enrichment (Stanley et al., 1986). Depending on con-
ditions such as nutritive state, power output, duration of activity,
and arterial lactate concentration, working muscle may switch
from net release to consumption (Brooks et al., 1998; Bergman
et al., 1999b). As well, tissues other than working muscle can
produce lactate, and if arterial lactate concentration rises suffi-
ciently, working muscle can become a lactate consumer as seen
in men exercising at sea level, on acute exposure to 4300m alti-
tude, and after 3 weeks of acclimatization to 4300m altitude on
Pikes Peak (Brooks et al., 1998). For the heart, net uptake is typ-
ical (Gertz et al., 1988), with few reports of lactate net release
from the working heart (Gertz et al., 1981). In the example shown
(Figure 1), net lactate release from the legs of a trained bicy-
clist causes arterial lactate concentration to rise at exercise onset.
However, as exercise continues, lactate clearance mechanisms,
including lactate uptake and oxidation by the heart reduce the
circulating lactate load. Data in Figure 1 also show that myocar-
dial lactate uptake and oxidation are concentration dependent. In
the figure “chemical lactate” extraction is equal to “net uptake”
based on [a-v] for chemical lactate concentration and myocar-
dial blood flow, which is equivalent to the cerebral metabolic
rate of lactate (CMRlac) terms used in studies of cerebral lac-
tate metabolism employing measurements of [a-v] and cerebral
blood flow (CBF). The dependence of cellular lactate exchange
on concentration difference is due to the fact that cell membrane
lactate transport proteins (Garcia et al., 1994, 1995) are sym-
ports that co-transport lactate anions and hydrogen ions (Roth
and Brooks, 1990a,b). Typically then, cells release lactate because
of intracellular glycolysis and lactate accumulation, whereas lac-
tate consumer cells such as heart, liver, kidneys, and red skeletal
FIGURE 1 | Arterial lactate level (upper graph) and a comparison of
myocardial tracer-measured (isotopic) lactate extraction, lactate
oxidation, and chemical extraction based on (a-v) and myocardial
blood flow (lower graph) are shown for a trained bicyclist whose
arterial [lactate] fell during moderate-intensity exercise. The results
show that net lactate exchange measurements underestimate total lactate
production, that most lactate produced is oxidized, and that lactate uptake
is concentration dependent. From Gertz et al. (1988).
muscle contain a high mitochondrial density which lowers intra-
cellular [lactate] relative to arterial and interstitial [lactate]. In
the brain, as in other tissues lactate exchange among neurons
and other cell types depends not only on the metabolic rates
within cells, but also on the extracellular environment which is
influenced by cellular metabolism as well as vascular delivery and
removal.
Given the existing literature on lactate metabolism in human
muscle and heart it should not be surprising that the healthy
human brain displays similar features (Glenn et al., 2003, 2015;
van Hall et al., 2009; Wyss et al., 2011), brain lactate turnover
is the norm and occurs during net release as well as net uptake.
In brain, as well as other tissues, glucose is taken up, glycolysis
occurs, and lactate is produced. However, because lactate is also
taken up, the CMR for lactate depends on the balance of cerebral
production plus uptake vs. disposal, which is mainly oxidation
(Glenn et al., 2015).
Science is difficult enough, and in the case of lactate
metabolism understanding is complicated by the use of different
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terms in different fields. Hence, we need to define terms as
they appear in this review. For brain, cerebral metabolic rate for
glucose (CMRgluc) equals the arterial-venous difference for glu-
cose (i.e., [a-v]gluc) times CBF: CMRgluc = (AVDgluc) (CBF).
Similarly, for lactate (CMRlac) equals the arterial-venous differ-
ence ([a-v]lac) times CBF: CMRlac= (AVDlac) (CBF). As already
noted, in skeletal (Stanley et al., 1986; Bergman et al., 1999b) and
cardiac muscle (Gertz et al., 1988; Bergman et al., 2009), and lung
(Johnson et al., 2012) physiology, the term net lactate exchange is
equivalent to CMRlac and in these instances the negative sign (−)
indicates net lactate release, whereas a positive sign (+) indicates
net lactate uptake. For Figure 2 on cerebral net lactate exchange
(>0 sign, and dark area) indicates net cerebral lactate release,
whereas the (<0) sign and light area indicates lactate uptake as
shown for control subjects and patients after suffering traumatic
brain injury (TBI). In the first days following injury most patients
display net cerebral lactate uptake transitioning to net release as
in controls after several days of intensive care. This said, whether
positive or negative, the CMR for lactate underestimates pro-
duction because of simultaneous production and removal within
brain tissue (van Hall et al., 2009; Glenn et al., 2015) as it does in
other tissues such as skeletal muscle (Stanley et al., 1986; Bergman
et al., 1999b) and heart (Gertz et al., 1988).
As illustrated by the use of equivalent terms “net glucose
uptake” and “CMRgluc” in muscle and brain metabolism fields,
a larger hurdle must be negotiated to achieve understanding of
the significance of tissue turnover. For tissues such as muscle
and brain that are net glucose consumers, tracer- and chemical
FIGURE 2 | Cerebral metabolic rate (CMR) for chemical lactate
[CMRlac = (CBF) (a-v)lac] over time in patients with severe TBI. To
illustrate the change in CMRlac over time, data presented as percentage of
patients demonstrating net cerebral lactate uptake (i.e., CMRlac < 0, white
area) compared percentage of patients demonstrating cerebral net lactate
release (i.e., CMRlac > 0, dark area). Patients display wide variability and
significant changes over time with regression to control values of net
cerebral lactate release over time. As illustrated in Figure 1, CMRlac
underestimates total lactate production. Redrawn from Glenn et al. (2003)
and ongoing studies with control values courtesy of T. C. Glenn.
measures of glucose yield equivalent results because glucose is
not produced in muscle (Bergman et al., 1999a) or brain (Glenn
et al., 2015). However, muscle (Stanley et al., 1986; Bergman
et al., 1999b), and brain (van Hall et al., 2009; Glenn et al., 2015)
simultaneously consume and produce lactate. Therefore, to know
muscle or brain lactate turnover rate both uptake and release need
to be measured and summed to calculate total lactate production.
Realization that tissue “net lactate” and “CMRlac” provide
data on only part of the story leads to insight into meaning of
the term “lactate production,” and its use, or misuse as too often
investigators will mistake the terms lactate “accumulation” and
“net release” to mean “lactate production.” Such misuse of termi-
nology is more than careless; the misuse reflects lack of under-
standing and can lead to misinterpretation of data and missed
opportunities for intervention in the intensive care unit (ICU).
GLYCOLYSIS AND “HYPERGLYCOLYSIS” AFTER CEREBRAL
INJURY
Glucose uptake and glycolysis are features of normal cerebral
metabolism, but trauma affects CMRgluc and glycolysis in spe-
cific ways. In particular, there is a relative increase in glycoly-
sis, a “hyper-glycolysis” that is a recognized feature of cerebral
metabolism immediately after injury (Bergsneider et al., 1997).
As part of the sympathetically mediated fight and flight mech-
anism (Selye, 1950; Selye and Fortier, 1950), both glycogen and
glucose are precursors to glycolytic flux. However, compared
to muscle in which glycogen content is typically 1.25 g/100 g
(1mMol/100 g tissue) (Hultman, 1967; Krssak et al., 2000), and
liver in which glycogen storage can be several times greater than in
muscles of well-nourished individuals (20–40mMol/100 g tissue)
(Nilsson and Hultman, 1974; Roden et al., 2001), cerebral glyco-
gen content is very small (0.3–0.4μMol/100 g tissue) (Oz et al.,
2007). Accordingly, it is understandable that cerebral glycogen
is rapidly recruited and depleted following acute injury. Limited
cerebral glycogen reserves point to the importance of the contin-
uous delivery of carbohydrate energy sources to the brain, always
(Glenn et al., 2003; van Hall et al., 2009), and especially follow-
ing injury (Glenn et al., 2003; Vespa et al., 2012). Not to confuse
cerebral substrate delivery and use with the US Federal Budget,
the human brain is definitely “pay as you go,” with deficits in oxy-
gen, substrate, both or either, having significant effects on tissue
function and viability.
In the field of cerebral metabolism, the term “hyperglycolysis”
is a relative term used to connote the extent of metabolic crisis
following injury. Following injury, depression of brain functions
are indicated by the decrements in cerebral oxygen consump-
tion rate (CMRO2) as well as glucose uptake and use (CMRgluc).
Hence, the presence of hyperglycolysis is indicated by a fall in
the normal molar ratio (MR), or “Metabolic Ratio” of 6/1 for
CMRO2/CMRgluc, the stoichiometry for complete glucose oxi-
dation being given as: 6 O2+ C6H12O2 → 6 CO2+ 6 H2O.
The fall in cerebral MR following injury is indicative of a rela-
tive increase in the role of glycolysis leading to cerebral lactate
production (Glenn et al., 2015), as well as an increase in pen-
tose phosphate pathway activity (Dusick et al., 2007). Reiterated,
the state of “hyperglycolysis” indicates an increase in glycolysis
relative to cerebral oxygen consumption.
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Because brain cells depend on glycolysis from carbohydrate
energy sources, while at the same time possessing limited capacity
for glycogen reserves, the importance of cerebral glucose deliv-
ery in health and disease cannot be overstated. The homeostatic
setpoint for blood glucose concentration is 5mM (≈100mg%),
whereas typical circulating blood [lactate] is <1mM (<9mg%),
and [pyruvate] and [β-OH butyrate] are in the μM range
(<1mg%). Restated, vascular glucose mass is 10-fold or more
greater than the circulating alternative CHO energy sources com-
bined. Hence, it is to be expected that maintaining euglycemia
from exogenous nutritional support is of major importance in the
neural ICU. This can perhaps be illustrated best by the better out-
comes of TBI patients as a result of careful assessment and early
enteral and parenteral nutritional support (Wang et al., 2013).
However, without knowledge of the metabolic and nutritional
status of the individual patient, the practice of medicine using
means-based administration of nutritional support and insulin
therapy (van den Berghe et al., 2001) can result in over- and
underfeeding, hyper- and hypoglycemia (Van den Berghe et al.,
2006; Henderson and Finfer, 2009; Marik, 2009; Myburgh and
Chittock, 2009) because assessments of the patient are based
solely on blood metabolite concentration measurements. The
use of [glucose] and the treatment of hyper- and hypoglycemia
with insulin without consideration of individual flux can poten-
tially result in medical care that creates the condition that is
then subsequently treated. Infusion of exogenous glucose at a
rate greater than patients’ individual glucose turnover will cause
hyperglycemia. This is then treated using insulin to maintain
glycemia. A better approach would be to utilize the autoregulatory
functionality that is intact (Glenn et al., 2014) and monitor glu-
cose production rate (i.e., Ra) to control the individual patient’s
[glucose]. Given current and anticipated technological advances,
such as stable isotope technology and rapid analysis, it should be
possible for attending clinicians to continually monitor an indi-
vidual patient’s body energy state (BES) and to deliver precision
nutritive care by adjusting enteral and parenteral nutrient delivery
over the course of treatment. Restated, while the field of nutrition
and pathophysiological metabolic pathways is pursued heavily by
scientists and physicians worldwide, and late vs. early enteral and
parenteral guidelines are desired for the treatment of the critically
ill and injured (Casaer et al., 2011b), means based titrating blood
[glucose] with insulin (Meijering et al., 2006) or standardized
equations describing caloric needs for healthy individuals (Harris
and Benedict, 1918) cannot describe the intra-patient metabolic
and nutritional variability (Glenn et al., 2014).
HINTS AT ELEVATED CEREBRAL LACTATE METABOLISM
POST-INJURY
Brain injuries are complicated and produce highly variable effects,
not only between patients, but temporally within patients with
seemingly confounding and contradictory effects. For example,
hyperglycolysis is typical post-TBI (Bergsneider et al., 1997),
and was observed by Glenn et al., who saw TBI to signif-
icantly decrease cerebral MR (Glenn et al., 2003). However,
even though injury depressed cerebral MR, many TBI patients
demonstrated cerebral net lactate uptake in the hours post injury
(Figure 2). Hence, puzzlingly hyperglycolysis coincided with a
positive CMRlac, or increased net lactate uptake. UCLA investiga-
tors took the apparently paradoxical results to indicate that some-
thing extraordinary was happening to brain CHO metabolism
post injury (Glenn et al., 2003).
That the human brain could take up and use lactate as a fuel,
not simply take up and accumulate lactate was entirely consistent
with extensive literature reports on cerebral metabolism in lab-
oratory rodents and rodent brain slices and tissue preparations.
Not only do astrocytes and neurons contain lactate transporters
(MCTs) necessary for cellular uptake (Pellerin et al., 2005; Pierre
and Pellerin, 2005), but importantly also mitochondria of neu-
rons contain MCTs and other components of the mitochondrial
lactate oxidation complex (mLOC) (Hashimoto et al., 2008) nec-
essary for neuronal lactate oxidation. Again, as described in the
introductory chapter (Schurr, 2014), in comparison to glucose,
rodent brain slices and neuronal preparations preferentially take
up and oxidize lactate in comparison to glucose (Schurr, 2006,
2008; Schurr and Payne, 2007). Although controversial a decade
ago (Glenn et al., 2003), the hint of cerebral lactate oxidation
following injury has been elaborated upon with results of basic
science studies on laboratory animals (Schurr and Payne, 2007)
and clinical research studies on humans (Smith et al., 2003;
Gallagher et al., 2009; Ichai et al., 2009, 2013; Wyss et al., 2011;
Jalloh et al., 2013; Bouzat et al., 2014; Glenn et al., 2014).
BODY SUPPORTS THE BRAIN
Along the way to studying cerebral glucose-lactate interactions
in patients following TBI an unexpected result emerged on our
TBI patients given standard of care treatment in state of the art
facilities by the dedicated and highly trained health care profes-
sionals. This was the herculean effort of the body to mobilize
energy resources for the injured brain (Glenn et al., 2014). With
reference Figure 2, patients were enrolled in our isotope tracer
studies involving use of primed-continuous infusions of [6,6-
2H2]glucose (i.e., D2-glucose) and [3-13C]lactate to track whole-
body and cerebral glucose-lactate interactions in TBI. Patients
were studied as soon as permission of legal representatives could
be obtained, usually 96–140 h after injury at which time numer-
ous parameters were approaching control levels. The time lag
had to do with mechanics of securing permission of patients’
legal representatives to conduct studies on patients receiving stan-
dard of care treatment. Consequently, at the time of study arterial
glucose (Figure 3A) and lactate (Figure 3B) concentrations in
patients were not significantly different from those in fasting con-
trol subjects. However, compared to values in control subjects,
in TBI patients CMRgluc was significantly depressed (Figure 4A)
(p < 0.01), whereas consistent with Figure 2 values, CMRlac was
similar to control values (Figure 4B).
As with glucose and lactate concentration levels, whole body
glucose turnover (Ra shown) in treated TBI patients was simi-
lar to values in controls (Figure 5A). Due to variability in TBI
patients, the slightly higher glucose Ra in patients was not sig-
nificantly different (P = 0.06), but trends toward indicating a
hypermetabolic state, or, in comparison to exercising controls,
a moderate intensity of exercise similar to a brisk walk. Again
the intra-patient variability demonstrated that some patients
were more hypermetabolic than others, and therefore would
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FIGURE 3 | Arterial glucose (A) and lactate concentrations (B) in
control and TBI patients. Values were constant over time, so mean values
for min 60, 90, and 120min are shown. Solid lines represent TBI patients
(n = 12) while dashed lines are normal control subjects (n = 6). This and
subsequent figures depict the following components: median (light circle),
mean (dark circle), standard deviation (heavy vertical bar), box-plot whisker
(thin vertical bar) and a kernel density estimation of the data distribution
(replacing the box-plot’s rectangular depiction) following Hintze and Nelson
(1998) as visualized by R package “Caroline” (Schruth, 2012). When
coincident, the median circle symbol obscures the mean symbol. TBI
patients demonstrated arterial glucose and lactate levels similar to those in
healthy control subjects. From Glenn et al. (2014).
FIGURE 4 | Cerebral metabolic rates (CMR) for glucose (A) and lactate
(B), in control and TBI patients; CMR = (Metabolite AVD) (Cerebral
Blood Flow), alternatively termed net exchange. Values were constant
over time, so mean values for min 60, 90, and 120min are shown. Solid
lines represent TBI patients (n = 12) while dashed lines are normal control
subjects (n–6); other aspects of the figure described in the legend to
Figure 3, above. Figures show net glucose uptake and net lactate release.
Compared to values in controls, CMRgluc, but not CMRlac, was depressed
in TBI patients. From Glenn et al. (2015).
require increased nutritional support as their body energy stores
are depleted more rapidly. However, even though arterial [lac-
tate] was similar in control subjects and patients, blood lactate
turnover (Ra shown) was elevated by ≈90% in TBI patients
compared to controls (Figure 5B). Because in this investigation
we lacked AVD and blood flow measurements across tissues
other than brain, we can only speculate that the sites of lactate
release were muscle (Bergman et al., 1999b) and the integument
(Johnson and Fusaro, 1972) as is found in normal physiology.
Since blood glucose and lactate concentrations were similar in
controls and patients the natural tendency was to conclude that
not much was happening other than blood glucose homeostasis
had been achieved. However, such a conclusion would not have
been correct.
FIGURE 5 | Hepatic (+ renal) glucose production, Ra (A) and body
lactate appearance rate (B) in control and TBI patients. Values were
constant over time, so mean values for min 60, 90, and 120min are shown.
Solid lines represent TBI patients while dashed lines are normal control
subjects. Due to variability in TBI patients, the tendency for higher glucose
production was NSD (P = 0.06). However, whole-body production
was ≈ 90% higher in TBI patients than healthy controls (P < 0.01). From
(Glenn et al., 2014).
Because we could measure the incorporation of 13C into blood
glucose from infused [3-13C]lactate, the rate of gluconeogene-
sis (GNG) from lactate and the percentage of circulating glucose
formed from lactate could be measured. Compared to values
of 15.2% of glucose Ra from lactate in control subjects, most
(67.1%) circulating glucose in TBI patients came from lactate
(Figure 6). These dramatic, and fundamentally paradigm chang-
ing results made possible because of the use of dual isotope tracer
studies would not have been envisioned from contemporary
measures of blood metabolite concentrations (Figures 3A,B).
With the linked-goals of reducing time in the intensive care
unit and improving patient outcomes, and recognition that TBI
patients given best standard of care treatment are in a catabolic
state, presents challenges, but offers opportunities to improve TBI
patient care and improve patient outcomes by providing nutritive
support to the injured, but recovering brain.
BRAIN RUNS ON LACTATE BOTH DIRECTLY AND INDIRECTLY
The central role of glucose in sustaining brain metabolism has
long been recognized (Scheinberg and Stead, 1949; Scheinberg
et al., 1965; Cahill et al., 1968; Sokoloff, 1973; Dienel and
Hertz, 2001), with classic and contemporary results (Glenn
et al., 2003, 2015) in accord. These rare, but extremely impor-
tant data contribute in major ways to the understanding of
cerebral metabolism in normal and pathological conditions,
including the formation of dietary reference intakes for car-
bohydrate nutrition (Medicine, 2005), the values for Estimated
Daily Requirement (EAR) and Recommended dietary Allowance
(RDA = EAR ± 2SD) for carbohydrate to provide cerebral needs
100 and 130 g/day, respectively.
Contemporary measurements show that despite hyperglycol-
ysis on injury, CMRgluc is decreased in the days following TBI
(Figure 4A) (Glenn et al., 2015). Again, in the patients stud-
ied, chemical concentration based measurement of CMRlac was
not significantly different from control values (Figure 4B) (P >
0.05). Like decreased CMRO2, decreased CMRgluc following TBI
may reflect the presence of intrinsic cerebral mechanisms to allow
the injured brain to “rest” in recovery. Alternatively, decreased
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FIGURE 6 | Percent contribution of lactate to glucose production
(gluconeogenesis, GNG) in healthy controls (dashed lines, n = 6) and
TBI patients (solid lines, n = 12). Values significantly greater following
TBI, p < 0.05. Trauma caused a major change in gluconeogenesis from
lactate. From Glenn et al. (2014).
cerebral metabolism following injury may be representative of an
injury-induced metabolic crisis, the latter being associated with
poor patient outcomes (Stein et al., 2012). Hence, the emphasis in
this review is to optimize substrate availability to promote healing
of the injured brain.
By comparison with results from studies on healthy control
subjects the importance of GNG from lactate in supplying glucose
for the brain is shown in Figure 7. In TBI patients the pat-
tern of glucose production from hepatic gluconeogenesis (GNG)
vs. glycogenolysis (GLY) is very different from that in healthy,
postabsorptive control subjects in whom GNG contributes only
16% of hepatic glucose Ra whereas GNG contributes 64% to glu-
cose Ra in TBI. Clearly, following TBI endogenously produced
lactate definitively supports brain metabolism via GNG; we term
this “indirect” brain fueling following TBI (Glenn et al., 2015).
However, lactate is also directly taken up and oxidized by injured
and healthy brains; we term this “direct” brain fueling by lactate.
Until advent of advanced technologies, such as the use of iso-
tope tracers (van Hall et al., 2009; Glenn et al., 2015), cerebral
lactate metabolism in healthy and brain-injured individuals was
anticipated from results of AVDlac and CMRlac measurements
(Figures 2, 4B) and experimentation on animal brain prepara-
tions (Schurr, 2008), but the extent of cerebral lactate turnover
could not be assessed because of simultaneous lactate production
and oxidative disposal within the tissue.
Figure 8A shows cerebral lactate fractional exaction (FExlac)
to approximate 10% in both healthy control subjects and those
suffering TBI (Glenn et al., 2015). Incidentally, the FEx for glu-
cose also approximates 10% in healthy subjects and TBI patients
(Glenn et al., 2015), so the value of 10% FEx for lactate is in
the range of biological plausibility. Nonetheless, knowing CBF,
arterial [lactate] and FExlac, cerebral tracer-measured lactate
uptake (TMUlac) can be determined and compared to 13CO2
excretion. With our moderate and severe TBI patients studied
5.7± 2.2 days after injury tracer-measured cerebral lactate uptake
was not different from values measured in healthy control sub-
jects (Figure 8B). Then, knowing and summing net lactate release
(CMRlac) and cerebral tracer-measured lactate uptake (TMUlac),
total cerebral lactate production can be determined (Figure 9).
As shown in Figure 9, the conceptual model of cerebral lactate
metabolism developed from seeing concentration-based depic-
tions, such as arterial [glucose] and [lactate] (Figure 3), and
CMRgluc and CMRlac (Figure 4), is very different from that
developed from knowledge of total cerebral lactate production
(Figure 9). To reiterate, new information of whole-body and cere-
bral glucose-lactate interactions show that glucose metabolism is
suppressed following TBI, but lactate metabolism is intact. This
knowledge provides impetus to explore the possibility of sup-
porting cerebral carbohydrate metabolism and improving patient
outcomes following injury by providing formulations containing
lactate and other monocarboxylates.
Based on measurements of cerebral tracer-measured lactate
uptake (TMU) (Figure 8B) and simultaneously measured 13CO2
excretion into the jugular bulb, cerebral lactate oxidation is
essentially 100% (Figure 10). Among various things the data
indicate that lactate entering the brains of healthy controls and
TBI patients is not simply stored, but utilized as a fuel energy
source. Importantly, the results (Figure 11) show that the brain
oxidizes lactate directly, which is supported by evidence of the
mLOC being present in the only species (rat) examined to date
(Hashimoto et al., 2008).
With the benefit of simultaneous CBF as well as arterial and
jugular bulb concentration and isotope enrichment measure-
ments for glucose and lactate it has been possible to partition
total cerebral carbohydrate uptake in healthy controls and TBI
patients (Figure 11). These results are consistent with what has
been known about cerebral metabolism, but importantly they
also provide novel insights into cerebral carbohydratemetabolism
in healthy control subjects and TBI patients as the sum of glucose
and lactate uptake equals total cerebral carbohydrate metabolism.
In healthy controls cerebral glucose uptake accounts for
15–25% of blood glucose disposal (Scheinberg and Stead, 1949;
Scheinberg et al., 1965; Cahill et al., 1968; Sokoloff, 1973; Dienel
and Hertz, 2001), and for the first time this has been validated
using tracer technology (Glenn et al., 2015). The percentage varies
depending on conditions, with time since eating a major fac-
tor because GNG is suppressed by the arrival of dietary energy,
CHO and macronutrients (Trimmer et al., 2002). Now, because
of our simultaneousmeasurements of body and brain glucose and
lactate fluxes we gain additional insights into total cerebral carbo-
hydrate metabolism, and therefore introduce the termCMRCHO.
In well-nourished postabsorptive controls glucose production
from hepatic glycogen provides 76% of cerebral carbohydrate
needs, with 15% of the total of glucose produced from lactate
via gluconeogenesis, the latter representing the indirect contribu-
tion of lactate. Direct cerebral lactate uptake represented 9% of
cerebral CHO needs in control subjects (Figure 11A). In contrast,
while CMRgluc is suppressed following brain injury, and glucose
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FIGURE 7 | By supporting gluconeogenesis, lactate indirectly
supports CMR glucose. The relative contributions to CMR
glucose from hepatic gluconeogenesis (GNG), and glucose from
hepatic glycogenolysis in healthy control subjects (Left, A), and
TBI patients (Right, B). A comparison of (A) (control) and
(B) (TBI) shows the large increase in percentage cerebral glucose
uptake contributed by GNG from lactate following TBI. From
(Glenn et al., 2015).
FIGURE 8 | Cerebral lactate fractional extraction (A) and
tracer-measured cerebral lactate uptake (B) in healthy control subjects
and TBI patients. Solid lines represent TBI patients while dashed lines are
normal control subjects. Both fractional extraction and lactate uptake are
preserved in TBI patients indicating plausibility of increasing cerebral lactate
uptake by raising arterial [lactate] by means of exogenous lactate infusion.
From (Glenn et al., 2015).
still represents 90% of CMRCHO, gluconeogenesis from lactate
provides 58% CHO energy supply, and the relative contribu-
tion of lactate uptake remains at 10% (Figure 11B). Hence, most
energy supplied to the injured brain comes directly, or indirectly
from lactate.
Like Figures 4A, 6 shows that CMRgluc is suppressed in TBI
patients. However, besides the effect of TBI on cerebral CHO
needs and CMRgluc, the side-by-side comparison in Figure 7
shows a very different pattern of cerebral carbohydrate energy
source in patients following TBI. While glucose still provided
most CHO-energy, most (59%) glucose came indirectly from lac-
tate via GNG, and 9% came from direct lactate uptake in TBI
patients making the total lactate or lactate-derived contribution
68% of total CHO energy as opposed to 25% in controls.
CLINICAL APPLICATIONS: EXOGENOUS LACTATE INFUSION
STUDIES
BRAIN NEEDS
As described here and in related papers (Glenn et al., 2014,
2015), several recent realizations lead to the question: “is vascu-
larly infused lactate an alternative brain fuel?” On one hand, if
lactate is the major oxidative energy source, how can it be consid-
ered as an alternative when it is, in fact “the fuel?” However, on
the other hand, if cerebral glycolysis is blocked after injury, then
lactate formulations are substances that health care givers can
administer to supplement, or augment vascular nutrient delivery
to an injured brain. In the latter case, formulations contain-
ing lactate salts, esters and other compounds would effectively
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FIGURE 9 | Components of cerebral lactate metabolism: Release
(CMRlac), Tracer-Measured Uptake and Total Cerebral Lactate
Production = TMU-CMRlac. Solid lines represent TBI patients while
dashed lines are normal control subjects. The use of [13-13C]lactate tracer
allow a very different view of cerebral lact production. Should CMRlac be
taken as a measure of lactate production, total lactate production would be
grossly underestimated. Regardless, whether estimated from CMR or total
lactate production, control subjects and TBI patients show similar capacities
for lactate uptake, release and production. From Glenn et al. (2015).
FIGURE 10 | Cerebral lactate Oxidation in control and TBI patients.
Values given in relative terms (% lactate uptake that is oxidized). Lactate
taken up by healthy controls and TBI patients is oxidized directly within the
tissue. Values corrected for the contribution to cerebral release of 13CO2
from the oxidation of 13C-glucose produced from circulating [3-13C]lactate.
From (Glenn et al., 2015).
augment the typical dextrose solutions currently used to sup-
port TBI patients. At a minimum, the exogenous glucose should
not be administered at a rate greater than the glucose turnover
rate of the individual patient. Such a practice would inevitably
FIGURE 11 | Absolute and relative contributions to total cerebral
carbohydrate (CHO) from lactate, glucose from gluconeogenesis
(GNG), and glucose from hepatic glycogenolysis (GLY = Glucose Ra –
GNGgluc) in healthy control subjects (Left, A), and TBI patients (Right,
B). Compared to (A), panel (B) shows the decrease in total CHO use and
CMRgluc following TBI, but increased contributions of lactate and glucose
from GNG to total cerebral CHO uptake after TBI. A comparison of
(A) (control) and (B) (TBI) shows the large increase in percentage cerebral
CHO uptake contributed by lactate, directly, or indirectly, in comparison to
healthy controls who have hepatic GLY available for to support CMRgluc.
From Glenn et al. (2015).
result in hyperglycemia and require insulin treatment. Seemingly,
a better alternative would be to support glycemia by providing
lactate and other monocarboxylate formulations that would allow
the liver and kidneys to maintain euglycemia as is typically seen
with exogenous lactate infusions (Miller et al., 2002a,b; Bouzat
et al., 2014).
Although not widely recognized, exogenous vascular infusion
of sodium lactate-lactic acid mixtures has been utilized to study
substrate kinetics in dogs (Issekutz and Miller, 1962), rats (Guo
et al., 2009; Johnson et al., 2011, 2012), and humans (Miller et al.,
2002a,b, 2005; Ichai et al., 2009, 2013). The latter studies estab-
lished short-term safety of the method of infusing concentrated
lactate solutions for several hours into healthy men with good
renal function to manage the sodium load and respiratory alka-
losis (Miller et al., 2005). Importantly, studies have commenced
with the intent of determining the effects of sodium lactate infu-
sion in cerebral metabolism following TBI (Ichai et al., 2009;
Bouzat et al., 2014; Glenn et al., 2015). In addition to the infusion
of sodium lactate, investigators have experimented with infusion
of hypertonic sodium pyruvate into swine to evaluate viability
of that approach for cardiac resuscitation and neuroprotection
following cardiac arrest (Sharma et al., 2005, 2008; Ryou et al.,
2009, 2010, 2012). In control beagles, nominal arterial lactate
and pyruvate concentrations are similar to those in humans (1.0
and 0.1mM, respectively), but, as used, sodium pyruvate infu-
sion increases arterial pyruvate and lactate concentrations to 3.5
and 8mM, respectively (Sharma et al., 2005), and so pyruvate
infusion may be an effective tool in managing blood and tissue
[L]/[P] while raising arterial [L] and [P].
LACTATE AND ITS ALTERNATIVES FOR BRAIN FUELING
Above we discussed some of the issues related to fueling the
injured brain, either by providing glucose or an alternative
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such as lactate or keto acids such as pyruvate, acetoacetate or
β-hydroxybutyrate. Aside fromwhat glycolysis produces and neu-
rons respire, numerous factors need consideration, some of which
are described here.
Lactate: We have advanced the idea that lactate enters the
mitochondrial reticulum via one or several MCT isoforms
and interacts with the mitochondrial Krebs Cycle and respira-
tory apparatus via a mLOC in muscle (Brooks et al., 1999a,b;
Dubouchaud et al., 2000; Hashimoto et al., 2006) and brain
(Hashimoto et al., 2008), and others have advanced the idea that
pyruvate enters themitochondrial matrix via pyruvate carrier iso-
forms (Bricker et al., 2012; Herzig et al., 2012). However, all seem
to agree that the monocarboxylates lactate and pyruvate traverse
cell membranes via MCT1 or MCT4 (Brooks, 2009; Divakaruni
et al., 2013). Plasma membrane MCT isoforms have different
affinities for monocarboxylates (Roth and Brooks, 1990a,b), but
it is clear also that in blood the monocarboxylates appear in con-
centrations that differ by an order of magnitude or more. For
instance, the nominal blood lactate/pyruvate ratio ([L]/[P] or
L/P) in arterial blood of < 10 can rise to > 300 in venous efflu-
ent of working human muscle (Henderson et al., 2007). Related
to the L/P in blood are the effects of LDH in erythrocytes and
the lung parenchyma that raise the L/P during each circulatory
passage (Johnson et al., 2011, 2012).
Operating under the assumption that because it is the prod-
uct of glycolysis and biological brain fuel (Schurr, 2014), we
(Miller et al., 2002a,b; Glenn et al., 2014) and others (Oddo et al.,
2012; Ichai et al., 2013; Bouzat et al., 2014) experimented on
supplementing nutritive supply to the injured brain with formu-
lations containing lactate or lactate anion. As described above,
lactate supports glycemia without causing hyperglycemia because
of hepatic autoregulation of blood [glucose]. Further, lactate is
taken up directly and oxidized by the healthy as well as injured
brain, and, importantly, in the ranges studied, uptake is not sat-
uration limited (Figure 8A). Importantly, and in contrast to the
case for working skeletal muscle in which lactate supplementa-
tion substitutes for glucose, following TBI in which glycolysis
is partially blocked, lactate supplementation via a 2mM lactate
clamp did not decrease CMRgluc, but instead raised total cere-
bral CHO uptake (unpublished data). This so called “sparing”
of blood glucose can then potentially be used for other cere-
bral metabolic priorities of glucose such as the neuroprotective
pentose phosphate pathway (Bartnik et al., 2005; Dusick et al.,
2007).
Short, several hour infusions of sodium lactate appear to
result in manageable sodium and alkalotic stresses in healthy
controls (Miller et al., 2005) and TBI patients with good renal
and respiratory function (Bouzat et al., 2014). Likely, how-
ever, for longer durations infusions of other lactate formula-
tions including organic salts (arginyl lactate), esters (glycerol
tri-lactate or N-acetyl lactate) or other compounds will need to
be developed and tested for safety and effectiveness in human
subjects.
Pyruvate: To reiterate from above, Mallet and colleagues
have developed sodium pyruvate infusion procedures and have
done extensive testing in animal models (Sharma et al., 2008;
Ryou et al., 2012). Typically the investigators utilize 2M sodium
pyruvate solutions for infusion via central venous lines (Sharma
et al., 2008). However, sodium pyruvate solutions are unstable
and give rise to noxious degradation products. To our knowledge,
neither sodium pyruvate nor pyruvate derivatives such as ethyl
pyruvate and N-acetyl pyruvate have been tested for safety and
effectiveness in human subjects. Moreover, the biological ratio-
nale for infusing pyruvate is questionable because it is rapidly
converted to lactate in blood (Sharma et al., 2005; Johnson et al.,
2011, 2012) and so the question arises what is the effective moiety
taken up by healthy and injured tissues.
Another advantage of exogenous lactate over pyruvate supple-
mentation relates to another chronic problem in the management
of TBI patients, that is the complication of hyperglycemia with
dextrose infusion and poor control of glycemia (Vespa et al.,
2012). A potential advantage of infusing lactate, a gluconeogenic
precursor, as opposed to dextrose for maintaining glycemic con-
trol is to take advantage of hepatic autoregulation of glucose Ra.
At present, extant data indicates that in both healthy individuals
(Miller et al., 2002a,b) and TBI patients exogenous lactate infu-
sion does not result in hyperglycemia (Bouzat et al., 2014). In
contrast, sodium pyruvate infusion results in hyperglycemia in
beagles (Sharma et al., 2005).
Given that both lactate and pyruvate are likely to traverse
plasma membrane, and hence blood-brain barrier thresholds by
MCTs that are capable of transporting either monocarboxylate,
a logical suggestion is to consider infusing mixtures of both lac-
tate and pyruvate, particularly if it is found efficacious to affect
the circulating L/P. For the present, however, given the liabilities
of infusing pyruvate compounds, there seems to be no practical
advantage of infusing pyruvate over lactate. In this context some
would argue that pyruvate is an effective ROS scavenger and is
neuro- and cardio protective (Mallet and Sun, 2003; Sharma et al.,
2008), but similar claims can be made for lactate (Rice et al., 2002;
Holloway et al., 2007; Schurr and Gozal, 2011; Alessandri et al.,
2012; Herzog et al., 2013; Bouzat et al., 2014).
Ketones: The “ketones” acetoacetate and β-hydroxybutyrate
cross plasma membrane and blood-brain barriers via facilitated,
MCT-mediated transport (Roth and Brooks, 1990a,b), but the
specialized MCT isoform appears to be MCT2 (Prins and Giza,
2006). Because acetoacetate and β-hydroxybutyrate gain access
to neurons via a unique isoform, thus minimizing crosstalk and
competition for transport among MCT isoforms, the approach
of using ketogenic diets to support cerebral healing in pedi-
atric populations is an area of active research (Prins and Hovda,
2009; Prins, 2012). Therefore, by extension of ongoing efforts it is
entirely reasonable to consider augmenting neuroplegic solutions
for iv infusion in the treatment of acute TBI with acetoacetate and
β-hydroxybutyrate.
As with other candidates for inclusion in neuroplegic solutions
acetoacetate and β-hydroxybutyrate would have advantages and
disadvantages. The ketones would contribute to whole body and
cerebral substrate availability, and thus would represent direct fuel
energy sources for the body and brain. However, ketones would be
unlikely to contribute to the maintenance of glycemia via GNG.
As well, acetoacetate and β-hydroxybutyrate would by necessity
be delivered as sodium salts with efficacy dependent on good renal
function.
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BODY AND BRAIN IN COMPETITION FOR NUTRIENTS IN THE ICU
[BODY ENERGY RESOURCE BUT NUTRIENT SINK]
Despite being treated according to current standard of care proto-
cols, in state of the art facilities, by talented and dedicated health
care professionals, as indicated by the very high rate of gluco-
neogenesis (Figure 5), our patients were undernourished. In our
companion reports (Glenn et al., 2014, 2015) we describe her-
culean efforts of the body, liver and kidneys to maintain glycemia
via GNG. Above we described possible uses of neuroplegic for-
mulations to sustain the injured brain and promote healing, but
efficacy of supporting the injured brain by providing intravenous
support needs to be considered within the context of overall,
whole-body nutrition. Whether delivered via a central or periph-
eral line, parenteral nutrition will go to where the circulation
takes it. Relative to other tissues, the brain is hypermetabolic and
is relatively well perfused in healthy and severely brain injured
individuals. However, most enteral and parenteral nutrition will
go elsewhere. For example, infused lactate is removed mainly
by oxidation in skeletal muscle (Bergman et al., 1999b; Miller
et al., 2002a,b; Emhoff et al., 2013). Hence, despite valiant efforts
to support the injured brain, both directly and indirectly from
endogenous sources (Glenn et al., 2014, 2015), so far as parenteral
nutrition is concerned the body is in competition with the brain
for resources. Hence, it is to be anticipated that the intravenous
infusion of neuroplegic solutions following TBI need to be con-
sidered on the background of overall enteral nutrition so that
overall nutrient and energy availability is sufficient to meet needs
of the brain and other tissues whether they be healthy or injured.
Assessing nutritional adequacy of patients in the ICU is a tech-
nical challenge. At best, results of indirect calorimetry are difficult
to interpret and the technology is difficult to employ, especially
in head injury cases, or when a patient is artificially ventilated.
Standardized equations (Harris and Benedict, 1918) force regres-
sion to population means, but cannot be expected to precisely
meet individual patient needs. The use of nitrogen balance, albu-
min and prealbumin measurements are also difficult to employ
and there are significant time lags between measurements and
ongoing changes in nitrogen balance. No wonder the literature is
rich with controversy over the benefits, or liabilities of providing
enteral or parenteral nutrition to patients (McClave et al., 1998;
Petros and Engelmann, 2006; Griffiths, 2007; Loh and Griffiths,
2009; Casaer et al., 2011a). However Wang et al. (2013) show in
a meta-analysis review of TBI treatments that providing enteral
and parenteral nutritive support early result in better patient out-
comes (Wang et al., 2013). In our view, such uncertainty involves
an inability to deliver personalized, precision care to patients.
Hence, newmethods of assessing BES in the ICU need to be found
to aid clinicians in delivering energy and nutrients sufficient to
cover needs for the body and brain. In this regard, %GNG is an
excellent candidate biomarker for assessing BES in the ICU, but
technology needs to be developed and validated for clinical use.
THE CONFUSED STATE OF UNDERSTANDING ON LACTATE CLEARANCE
Results of our investigations indicate that caution needs to be
applied when using the term “lactate clearance” as a biomarker
of the severity of traumatic injury (Zhang and Xu, 2014).
Without the use of isotope tracers, clearance is calculated as
net metabolite change over time with lactatemia and lactic
acidosis harbingers of poor outcome. In our investigation we
infused [3–13C]lactate tracer to determine metabolic clearance
rate (MCR = Rd/[lactate]a), units being (ml/kg/min). In our
investigation lactate production (Ra) and disposal (Rd) rates were
significantly elevated following TBI (Figure 4B) (Glenn et al.,
2014), while arterial lactate concentration ([lactate]a) was the
same in control subjects and TBI patients (Figure 3B). This
means that lactate MCR was very high and significantly greater,
not lower, in TBI patients compared to controls. Additional tracer
studies will be required to establish the relationship between
lactate MCR and outcome following TBI.
SUMMARY
Trauma to the brain results in a metabolic crisis (Stein et al.,
2012; Vespa et al., 2012), or crises as the mechanism of injury may
involve trauma to other body parts. The injured person is typically
hypermetabolic even if cerebral metabolism is suppressed follow-
ing injury (Glenn et al., 2003). Together, our results (Glenn et al.,
2014, 2015) and those of others (Gallagher et al., 2009; van Hall
et al., 2009; Jalloh et al., 2013; Bouzat et al., 2014) indicate a sig-
nificant role for lactate in cerebral normo- and pathophysiology.
Given that CMRgluc is suppressed following cerebral injury, it’s
possible to take advantage of the Lactate Shuttle mechanism of
supplying energy to bypass the restriction in glycolytic flux and
spare limited glucose reserves for other functions such as pentose
phosphate pathway activity.
As reviewed above, sodium lactate infusion is a logical first
step in translating new knowledge of cerebral lactate metabolism
into procedures and practices to provide nutritive support to the
injured brain. However, other lactate compounds or formulations
containing additional or other amendments may offer still greater
potential to nourish the injured brain in the context of an injured
or malnourished body. In the space available we have shown new
and dramatic results on body-brain interactions in moderate and
severe TBI patients. Those results not only show direct and indi-
rect nutritive support of the body for the brain, but the results
should alert scientists and clinicians alike to the possibility that
attempts to provide parenteral, vascular, support for the brain
will be met by an eagerly needy, and far larger body corpus that
can easily outcompete the injured brain for glucose and mono-
carboxylate alternatives. Therefore, by using glucose production
rate and %GNG as biomarkers for BES in individual patients
health care providers would have actionable data upon which to
personalize individual patient needs for delivery of energy and
nutrients required to support both brain and body needs. In
practical terms, with knowledge of BES health care profession-
als would have knowledge to provide energy and macronutrients
to meet corporal needs, as indicated by %GNG in the range of
25% (Horning and Brooks, 2012a,b). Then, via parenteral routes
monocarboxylate formulations designed specifically to supple-
ment cerebral energy needs could be delivered in an effort to
support cerebral repair and recovery following injury (Horning
and Brooks, 2012a,b).
Today the field of precision medicine focuses predominately
on genomics, but all variations of the omics, (i.e., application
of panomic analysis to individual disease) will participate (NIH,
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2011) in efforts to utilize the concept of precision medicine to
improve health care delivery, particularly in the area of managing
trauma. In fact, other omics constituting precisionmedicine (e.g.,
proteomics, metabolomics, and now fluxomics), as illustrated
through the use of %GNG as a biomarker for BES and treatment
using formulations targeting injured tissue, already might be
areas of interest. Indeed, segments of the biotech, medtech, dig-
ital health, and life sciences industries are spearheading medical
applications and exploring opportunities. With basis of know-
ing an individual patient’s BES, health care providers will be able
to practice precision medicine through use of personalized pre-
scriptions to deliver exogenous enteral and parenteral nutritive
formulations to maintain a body energy state, that neither over-
or underfeeds patients, but, importantly, provides directed nutri-
ent support for the injured brain. A personalized approach to
precision body energy state will therefore enable the clinicians
to support both the body and the brain during recovery from
trauma.
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